ClinicalTrials.gg
CompletedNCT03825744Updated Nov 7, 2024

Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

A Phase 3 interventional study of Hetrombopag Olamine+Standard Therapy and Placebo+Standard Therapy in Severe Aplastic Anemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Anemia, Aplastic with a site in China — 39 open to participants now, 43 under way, 1 of them phase 3. Anemia, Aplastic · China.

Enrollment
3rd of 74
240 · median 52
Started
2019
with 2 others
Phase 3
2 of 88
none open now
Registered
23rd of 88
by date
Lead sponsor
7 of 88
Jiangsu HengRui Medicine Co., Ltd.

Among the 88 studies in Anemia, Aplastic with a site in China, this one is the 3rd largest by enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 3, and was the 23rd registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

39 of the 88 studies in Anemia, Aplastic with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Anemia, Aplastic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, placebo-control, phase III study to investigate hetrombopag in subjects with severe AA who are treated naive.

180 treated naive patients with SAA will be enrolled in the study. The primary objective of the study will be the rate of complete hematologic response at six months.

03

Conditions studied

  • Severe Aplastic Anemia

Browse trials for

Keywords

  • SAA
04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.15 Years to 75 Years (weight greater than 50 kg if Age \< 18 years old). 2.Severe aplastic anemia characterized by Bone marrow cell proliferation less than 25 percent (If ≥25% but \<50%, the remaining hematopoietic cells should be \<30%) AND At least two of the following: \<0.5×109/L; count \<20×109/L; Absolute reticulocyte count \<20×109/L.

3.Unsuitable or unwilling to perform hematopoietic stem cell transplantation ().

4.Signed .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of whole blood cell reduction due to other causes or bone marrow hypoproliferative diseases.
  2. Subjects who have previously received therapy with mycophenolate mofetil, sirolimus, high dose cyclophosphamide (≥45mg/kg/d), alemtuzumab, etc;or have treated with thrombopoietin receptor agonist (eg, eltrombopag, romiplostim, rhTPO, etc.) prior to randomization.
  3. Previous history of hematopoietic stem cell transplantation.
  4. Subjects who is known or suspected of or to Hetrombopag's API (Active Pharmaceutical Ingredient).
  5. Evidence of clonal cytogenetic abnormalities at the time of screening.
  6. Bleeding and/or Infection not adequately responding to appropriate therapy.
  7. Any laboratory or clinical evidence for infection. Any clinical history for infection; chronic infection; or any evidence for active hepatitis at the time of subjects screening.
  8. > 2.5 x (ULN), AST> 2.5 x upper limit of normal (ULN) DBLI> 1.5 x upper limit of normal (ULN), Scr> upper limit of normal (ULN).
  9. Subjects with uncontrolled hypertension (>180/100mmHg), severe arrhythmia (such as complete left bundle branch block, prolongation (Bazetts formula), torsade ventricular tachycardia, etc.), unstable angina, pulmonary hypertension at the time of screening.
  10. Subjects diagnosed with cirrhosis or portal hypertension.
  11. Subjects with malignant solid tumors of any organ system within 5 years prior to screening, with or without treatment, or recurrence, except for local cutaneous basal cell carcinoma; subjects with hematological tumors found previously or during screening.
  12. Subjects with deep vein thrombosis, myocardial infarction, stroke or peripheral arterial embolization within 12 months prior to randomization.
  13. Female subjects who are nursing or pregnant.
  14. Subjects cannot comply with effective .
  15. Subjects have participated in other clinical trial within the 3 months prior to study entry.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Hetrombopag Olamine+Standard Therapy

    Drug: Hetrombopag Olamine+Standard Therapy

  • Placebo comparator
    Placebo+Standard Therapy

    Drug: Placebo+Standard Therapy

Interventions

  • DrugHetrombopag Olamine+Standard Therapy

    Drug page: Hetrombopag olamine

    once daily

  • DrugPlacebo+Standard Therapy

    once daily

06

What researchers measure

Primary outcomes

  1. Rate of complete hematologic response at six months.

    Time frame: 6 months

07

Study locations

1 site
  • Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300041, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jul 2024, 63 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2019
First posted
Jan 31, 2019
StartActual
Mar 5, 2019
Primary completionActual
Jul 3, 2024
CompletionActual
Jul 3, 2024
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03825744
Responsible party
Sponsor
First posted
Jan 31, 2019
Start date
Mar 5, 2019
Primary completion
Jul 3, 2024
Completion
Jul 3, 2024
Last update
Nov 7, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hetrombopag olamine

Start the discussion